---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-002724"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:48:56.739567+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Protagonist updates pipeline; icotrokinra NDA Jul '25, rusfertide NDA Dec '25; Phase 3 UC/CD initiated

## Summary
- Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.
- Rusfertide (hepcidin mimetic) NDA for polycythemia vera submitted Dec 29 '25; Phase 3 VERIFY met primary endpoint, p<0.0001.
- PN-881 (oral IL-17) Phase 1 started Q4 '25; PN-477sc triple agonist Ph1 initiation mid-'26; PN-8047 oral hepcidin dev candidate nominated Q4 '25.
- Up to $630M milestones from J&J plus 6-10% royalties; $200M opt-out payment from Takeda for rusfertide plus additional milestones.
- Total potential sales milestones from icotrokinra and rusfertide up to $1.2B.

## SEC filing metadata
- accession: 0001104659-26-002724
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465926002724/0001104659-26-002724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465926002724/tm262863d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-002724
- JSON: https://secwatch.observer/filing/0001104659-26-002724.json
- Plain text: https://secwatch.observer/filing/0001104659-26-002724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.